- Home
- FEBO vs PHGE Comparison
FEBO vs PHGE Comparison
Compare FEBO & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | PHGE |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | FEBO | PHGE |
|---|---|---|
| Price | $0.74 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 5.6K | ★ 62.5K |
| Earning Date | 12-16-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,110,653.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $0.61 | $4.10 |
| 52 Week High | $2.31 | $22.06 |
Technical Indicators
Market Signals| Indicator | FEBO | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 74.68 |
| Support Level | $0.65 | $4.10 |
| Resistance Level | $0.76 | $4.91 |
| Average True Range (ATR) | 0.04 | 0.30 |
| MACD | 0.00 | 0.39 |
| Stochastic Oscillator | 65.38 | 77.56 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).